Joseph H. Krushinski

Author

Also Known As

J. H. KRUSHINSKI, J. H. Krushinski, J.H. Krushinski, Joseph H Krushinski, Joseph H. Krushinski, Joseph Krushinski, Krushinski, J.H., Krushinski, Joseph H.

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)National Institute of Mental Health Karolinska Institutet National Institutes of Health

About

Joseph H. Krushinski is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	1.3K
2	Natural Sciences	8	8	264
3	Social Sciences	6	6	540
4	Engineering	1	1	11
5	Allergy	1	1	48

Joseph H. Krushinski

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake David T. Wong, Frank P. Bymaster, Douglas A. Mayle, Neuropsychopharmacology Norepinephrine UptakeMolecular PharmacologyMedicinePhysiologyPsychopharmacology	1993	221
The absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor David W. Robertson, Joseph H. Krushinski, R W Fuller, Journal of Medicinal Chemistry Psychotropic MedicationPsychopharmacologySelective Serotonin-uptake InhibitorOrganic ChemistryPharmacotherapy	1988	160
Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake F.P. Bymaster, E. E. Beedle, Jeremy Findlay, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyPsychiatryMedicinePsychotropic MedicationPsychopharmacology	2003	121
Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain David T. Wong, Frank P. Bymaster, Leroy R. Reid, Neuropsychopharmacology Serotonin UptakeMedicinePsychopharmacologyNeuropharmacologyPharmacotherapy	1993	109
The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain Fumihiko Yasuno, Amira K. Brown, Sami S. Zoghbi, Neuropsychopharmacology High Specific SignalCannabis UseNeurophysiologyMedicineFunctional Selectivity	2007	86
Synthesis, Ex Vivo Evaluation, and Radiolabeling of Potent 1,5-Diphenylpyrrolidin-2-one Cannabinoid Subtype-1 Receptor Ligands as Candidates for In Vivo Imaging Sean Donohue, Joseph H. Krushinski, Victor W. Pike, Journal of Medicinal Chemistry	2008	82
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-spiro[cycloalkane-1,3'-[3H]indol]-2'(1'H)-ones David W. Robertson, Joseph H. Krushinski, G. Don Pollock, Journal of Medicinal Chemistry	1987	80
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine David W. Robertson, E. E. Beedle, Joseph H. Krushinski, Journal of Medicinal Chemistry Combinatorial ChemistryHeterocyclicBiochemistrySeveral NoncatecholamineMedicine	1985	73
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain Virginia L. Lucaites, Joseph H. Krushinski, John M. Schaus, Naunyn-Schmiedeberg s Archives of Pharmacology Molecular PharmacologyMedicinePhysiologyReceptor (Biochemistry)Neuropeptide Receptor	2005	63
Dihydropyridazinone cardiotonics. The discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one David W. Robertson, Joseph H. Krushinski, E. E. Beedle, Journal of Medicinal Chemistry Medicinal ChemistryBioorganic ChemistryPharmacological StudyBiochemistryAntiparasitic Agent	1986	56

Page 1